List of works by Laura Novik

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

scientific article published on 21 February 2017

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

scientific article

Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

scientific article published in June 2016

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

scientific article published on 28 July 2020

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial

scientific article

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

scientific article published on 8 November 2006

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)

scientific article

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

scientific article (publication date: 2 February 2010)

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

scientific article (publication date: 9 May 2016)

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

scientific article

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

scientific article

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

scientific article published on 4 December 2017

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

article by Martin R Gaudinski et al published 2 March 2019 in The Lancet

Paulina is supported by:

About Paulina

Help